Inventor · disambiguated record
Andrea Allersdorfer
Also filed as: ALLERSDORFER ANDREA
26 granted patents·9 pending applications·69 citations·filing 2013–2022
95Inventor score
Top patents by PatentIndex Score
35 records- 0195US9884898B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Feb 6, 2018·17 cites·20 claims
- 0292US11345728B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted May 31, 2022·2 cites·14 claims
- 0392US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0489US10273275B2Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 30, 2019·10 cites·20 claims
- 0588US10774119B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 15, 2020·3 cites·13 claims
- 0687US11773147B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Oct 3, 2023·1 cites·20 claims
- 0787US10526384B2Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2013·Granted Jan 7, 2020·5 cites·16 claims
- 0883US10501510B2Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 10, 2019·4 cites·23 claims
- 0982US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 1082US10400016B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Sep 3, 2019·4 cites·25 claims
- 1182US9950034B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Apr 24, 2018·3 cites·20 claims
- 1280US10927156B2Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune responsePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Feb 23, 2021·1 cites·10 claims
- 1378US10329334B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Jun 25, 2019·1 cites·13 claims
- 1478US10118952B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Nov 6, 2018·1 cites·15 claims
- 1578US10072056B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 11, 2018·1 cites·18 claims
- 1678US10065998B2Proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2017·Granted Sep 4, 2018·1 cites·18 claims
- 1775US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 1875US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 1975US10316071B2Fusion moleculesSANOFI SA·Filed 2016·Granted Jun 11, 2019·2 cites·15 claims
- 2074US11168119B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Nov 9, 2021·1 cites·28 claims
- 2172US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 2269US9150629B2Human tear lipocalins which bind PCSK9 and methods of use thereofPIERIS AG·Filed 2014·Granted Oct 6, 2015·1 cites·56 claims
- 2366US10927154B2Multi-specific polypeptide useful for localized tumor immunomodulationPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Feb 23, 2021·1 cites·6 claims
- 2466US2018371038A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2566US2018371037A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2666US2018346532A1Novel proteins specific for pyoverdine and pyochelinSANOFI SA·Filed 2018·Application pending·0 cites
- 2763US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 2860US10787491B2Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Sep 29, 2020·0 cites·11 claims
- 2960US2020148733A1Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 3055US2018311311A1Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 3151US2024166763A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 3250US9598476B2Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9DAIICHI SANKYO CO LTD·Filed 2015·Granted Mar 21, 2017·0 cites·51 claims
- 3350US2023366884A1Biomarker methods and usesPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 3450US2017173112A1Novel binding proteins for pcsk9DAIICHI SANKYO CO LTD·Filed 2017·Application pending·0 cites
- 3548US2015369821A1Novel lipocalin-mutein assays for measuring hepcidin concentrationPIERIS AG·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrea Allersdorfer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →